CN Patent

CN112020352A — 用于痤疮的大麻素给药方案

Assigned to Botanix Pharmaceuticals Ltd · Expires 2020-12-01 · 5y expired

What this patent protects

用于治疗或预防痤疮的治疗方案，所述方案包括施用：a)50mg至3000mg的局部液体或凝胶组合物，所述组合物包含1％w/w至15％w/w的大麻素，其中大麻素是溶解于所述液体或凝胶组合物中。

USPTO Abstract

用于治疗或预防痤疮的治疗方案，所述方案包括施用：a)50mg至3000mg的局部液体或凝胶组合物，所述组合物包含1％w/w至15％w/w的大麻素，其中大麻素是溶解于所述液体或凝胶组合物中。

Drugs covered by this patent

Patent Metadata

Patent number
CN112020352A
Jurisdiction
CN
Classification
—
Expires
2020-12-01
Drug substance claim
No
Drug product claim
No
Assignee
Botanix Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.